Successful performance in proficiency testing (PT) is required
|
|
- Philip Gray
- 6 years ago
- Views:
Transcription
1 Performance Characteristics of Several Rules for Self-interpretation of Proficiency Testing Data R. Neill Carey, PhD; George S. Cembrowski, MD; Carl C. Garber, PhD; Zohreh Zaki, MD Context. Proficiency testing (PT) participants can interpret their results to detect errors even when their performance is acceptable according to the limits set by the PT provider. Objective. To determine which rules for interpreting PT data provide optimal performance for PT with 5 samples per event. Design. We used Monte Carlo computer simulation techniques to study the performance of several rules, relating their error detection capabilities to (1) the analytic quality of the method, (2) the probability of failing PT, and (3) the ratio of the peer group SD to the mean intralaboratory SD. Analytic quality is indicated by the ratio of the PT allowable error to the intralaboratory SD. Failure of PT was defined (Clinical Laboratory Improvement Amendments of 1988) as an event when 2 or more results out of 5 exceeded acceptable limits. We investigated rules with limits based on the SD index, the mean SD index, and percentages of allowable error. Results. No single rule performs optimally across the range of method quality. Conclusions. We recommend further investigation when PT data cause rejection by any of the following 3 rules: any result exceeds 75% of allowable error, the difference between any 2 results exceeds 4 times the peer group SD, or the mean SD index of all 5 results exceeds 1.5. As method quality increases from marginal to high, false rejections range from 16% to nearly zero, and the probability of detecting a shift equal to 2 times the intralaboratory SD ranges from 94% to 69%. (Arch Pathol Lab Med. 2005;129: ) Successful performance in proficiency testing (PT) is required of all clinical laboratories licensed under the provisions of the Clinical Laboratory Improvement Amendments of Acceptable limits are specified in terms of fixed concentrations, fixed percentages, a fixed concentration and a fixed percentage, or 3 times the PT peer group SD. Proficiency testing providers express participant results in a variety of formats. Some providers provide pass-fail scoring alone, while others provide SD index (SDI) scores and graphic presentations of each result s deviation from the target value as a percentage. When passing scores are obtained, users must interpret the PT data for themselves to determine whether the data indicate the presence of significant bias or random error. Careful self-examination of Clinical Laboratory Improvement Amendments of 1988 mandated PT data can be useful because there are 5 replicates in a single PT event, more than the 2 or 3 controls in a typical analytic run. Therefore, PT data have higher sensitivity to error than control data. The performance characteristics of several rules for interpreting PT data were previously studied. 2 Accepted for publication March 31, From the Peninsula Regional Medical Center, Salisbury, Md (Drs Carey and Zaki); University of Alberta Hospital, Capital Health Authority, Edmonton, Alberta (Dr Cembrowski); and Quest Diagnostics, Incorporated, Lyndhurst, NJ (Dr Garber). Dr Zaki is now with Doctors Pathology Services, Dover, Del. The authors have no relevant financial interest in the products or companies described in this article. Reprints: R. Neill Carey, PhD, Peninsula Regional Medical Center, 100 E Carroll St, Salisbury, MD ( neill.carey@ peninsula.org). Counting rules based on SDI limits and rules with limits based on the mean SDI were investigated. It was found that rule performance depended on the ratio of the survey group SD, s g, to the internal laboratory SD (intrainstrument SD), s i. It was also found that as s g /s i increases, the sensitivities of different rules change. While no single set of rules performed optimally throughout the range of s g / s i values encountered, screening with the SDI rule was recommended (see Table 1 for a list of rules investigated in the present study and their definitions). Follow-up was recommended on data that failed the screening rule with a combination of the and R 4.0 SDI or R 3.0 SDI rules to demonstrate random error and the x 1.5 SDI or x 1.0 SDI rules to demonstrate systematic error. The choice of range and mean rules depended on the value of s g /s i. In the present work, we studied the performance characteristics of additional rules and compared the sensitivities of the rules for detecting errors with the probability of failing PT. MATERIALS AND METHODS Using Minitab (Minitab Inc, State College, Pa), we designed a computer program similar to the one used previously to study the performance characteristics of different rules for interpreting PT results 2 and simulated PT performance for a typical automated chemistry analyzer. We used the group mean (x g) and group SD (s g ) for each PT sample from the 1991 College of American Pathologists C-C survey. 3 Three analytes were selected to span the range of quality (based on the ratio of allowable error to s i ) from Six Sigma 4 to marginal (Table 2): potassium, creatine kinase (CK), and iron. The intrainstrument SD (s i ) was obtained from the College of American Pathologists quality assurance group summary report for control products XLS-71 and XPS- Arch Pathol Lab Med Vol 129, August 2005 Self-Interpretation of Proficiency Testing Data Carey et al 997
2 Table 1. Quality Control Rules Studied*, at least 1 result exceeds x g 2.0 s g limit, at least 1 result in each of 2 events exceeds x g 2.0 s g limit, at least 2 results exceed x g 2.0 s g limit, at least 1 result exceeds x g 2.25 s g limit, at least 1 result exceeds x g 3.0 s g limit, at least 2 results exceed x g 3.0 s g limit x 1.0 SDI, mean of 5 samples exceeds x g 1.0 s g limit x 1.5 SDI, mean of 5 samples exceeds x g 1.5 s g limit R 3.0 SDI, difference between any 2 results exceeds 3.0 s g R 4.0 SDI, difference between any 2 results exceeds 4.0 s g, combination rule; invoke if any rule exceeds limit, 1 result exceeds 75% of analyte-specific allowable error 5 x &1 50% EA, all results are on the same side of the mean, and 1 result exceeds 50% of analyte-specific allowable error /5 x &1 50% EA, combination rule; invoke if any rule exceeds limit x 1.5 SDI / /R 4.0 SDI, combination rule; invoke if any rule exceeds limit 2 PT limit, fail PT event * SDI indicates SD index; x g, group mean; s g, group SD; EA, allowable error; and PT, proficiency testing. Table 2. Method Quality* Method Quality Sigma QC Requirement Unacceptable 2.0 Total analytic error cannot be maintained allowable error Marginal 2.0 to 3.0 QC procedures with high probability of false rejection and replicate measurements of patient and QC samples Fair 3.0 to 4.0 Multirule with 4 6 QC measurements per run Good 4.0 to 6.0 Multirule with 2 3 QC measurements per run Six Sigma 6.0 Weak QC procedures with 2 QC measurements per run * Adapted from Garber and Carey 4 and Westgard. 6 QC indicates quality control. Allowable error divided by intrainstrument SD, assuming bias is negligible. / combination control rule. For example, rule. 153, 5 which incorporated the data from approximately 30 Ortho Vitros 400s and 700s (formerly known as Kodak Ektachem). Control products XLS-71 and XPS-153 are aliquots of the same lot and were analyzed in the 1991 College of American Pathologists C-C survey. Parameter scenarios of simulated conditions for analytes are shown in Table 3. For potassium, s g /s i averaged We set the allowable error at 0.5 meq/l (Clinical Laboratory Improvement Amendments of 1988 limits 1 ). The ratio of allowable error to s i averaged 7.1, making the analytic quality of potassium at least Six Sigma (Table 2) using the classifications of Garber and Carey 4 and Westgard. 6 For CK, s g /s i averaged We set the allowable error at 15% (Quality Management Program Laboratory Services, previously Laboratory Proficiency Testing Program, Ontario Medical Association 7 ). The ratio of allowable error to s i averaged 3.8, making the quality of CK fair. For iron, s g /s i averaged We set the allowable error at 20% (Clinical Laboratory Improvement Amendments of 1988 limits). The ratio of allowable error to s i averaged 2.9, making the quality of iron marginal. For each analyte, we simulated trial analyses of groups of 5 PT samples per PT event. We quantified the performance characteristics of each rule in terms of its probability for false rejection (P fr, probability to signal an error for an event when only the inherent error of the method is present) and its probability for error detection (P ed, probability to signal an error for an event when increased systematic or random error is present). Figure 1 shows our concept of the performance characteristics of the ideal rule for interpreting PT data. The x-axis is the percentage of allowable error. At low percentages of allowable error, the probability of error detection (probability of rejection) for the rule is negligible. At a desired transition point, the probability of rejection increases rapidly until the rule is nearly 100% certain to reject and indicates that there is a potential problem with the method. Every rule has 3 performance characteristics: P fr, P ed for each amount of increased systematic error, and P ed for each amount of increased random error. We calculated P fr as the proportion of reject signals when only the inherent error of the method was included in the simulated events. We calculated P ed as the proportion of reject signals when each stated amount of systematic error (bias) or random error (imprecision) was included in the simulated events. We studied the rules listed in Table 1. These include the rules identified previously as optimally performing, 2 with exception of the SDI rule (which had high probability of false rejection, P fr.38 for potassium, a Six Sigma method). We included 2 new rules, (invoked when 1 result exceeds 75% of analytespecific allowable error, a near miss ) and 5 x &1 50% EA (invoked Table 3. Parameter Scenarios of Simulated Conditions for Analytes Analyte Units Allowable Error Group Mean Group SD Potassium meq/l 0.5 meq/l Creatine kinase U/L 15% Iron g/dl 20% Intrainstrument SD Sigma Arch Pathol Lab Med Vol 129, August 2005 Self-Interpretation of Proficiency Testing Data Carey et al
3 Figure 1. Power function for idealized proficiency testing rule. At low percentages of allowable error, the probability of rejection is negligible. At a desired transition point where the error is a significant proportion of allowable error, the probability of rejection increases dramatically. P ed indicates the probability for error detection. Figure 3. Performance characteristics of selected proficiency testing (PT) rules for systematic error for creatine kinase (mean s g /s i, 1.70; mean E A /s i, 3.8). P ed indicates the probability for error detection. Figure 2. Performance characteristics of selected proficiency testing (PT) rules for systematic error for potassium (mean s g /s i, 1.23; mean E A /s i, 7.1). P ed indicates the probability for error detection. Figure 4. Performance characteristics of selected proficiency testing (PT) rules for systematic error for iron (mean s g /s i, 2.68; mean E A /s i, 2.9). P ed indicates the probability for error detection. when all results are on the same side of the mean and 1 result exceeds 50% of allowable error). We also studied the probability of PT failure ( 2 results exceeding allowable error) as errors increase, to ascertain which rules can detect errors before PT failure occurs. We used the model for the participating laboratories used previously. 2 RESULTS Figures 2, 3, and 4 are graphs of the performance characteristics of selected rules for systematic error for potassium, CK, and iron, respectively. The x-axes of these figures differ slightly from the x-axis of Figure 1; they are labeled in terms of systematic error, expressed as bias measured in terms of the intrainstrument SD, s i.abiasof 0.0 s i corresponds to the probability of false rejection (P fr, the probability that the rule signals an error when none is present aside from the inherent random error of the method). Biases of 0.5 and 1.0 s i are small shifts relative to allowable error for most analytes, and biases of 2.0 and 3.0 s i are shifts that could cause PT problems for low-quality analytes. There are dramatic differences in the abilities of the different rules to detect errors that must be detected to pass PT. For potassium (Six Sigma quality), any rule except the rule will have sufficient power to detect significant errors without excessive false rejections. For iron (marginal quality at 2.9 Sigma), however, the only rules that can detect systematic error before there is significant risk of failing PT are the and 5 x &1 50% EA rules. Creatine kinase (fair quality at 3.8 Sigma) is transitional; the traditional counting rules detect significant errors; however, they are less sensitive than they are for potassium. The rule has a significant probability of false rejection for CK and iron (although less than the previously recommended SDI rule 2 ). In comparison, a quality control (QC) procedure for routine internal control with the 1 3s /2 2s combination control rule (a combination of the 1 3s and 2 2s control rules), using 2 controls, 8 has P ed of roughly.50 to detect a shift of 2.0 s i and a high probability of detecting a shift of 3.0 s i. Table 4 summarizes the performance of the rules we studied for detection of systematic error. Arch Pathol Lab Med Vol 129, August 2005 Self-Interpretation of Proficiency Testing Data Carey et al 999
4 x 1.0 SDI x 1.5 SDI Table 4. 5 x &1 50% EA /5 x &1 50% EA x 1.5 SDI / /R 4.0 SDI x 1.0 SDI x 1.5 SDI 5 x &1 50% EA /5 x &1 50% EA x 1.5 SDI / /R 4.0 SDI x 1.0 SDI x 1.5 SDI 5 x &1 50% EA /5 x &1 50% EA x 1.5 SDI / /R 4.0 SDI Probability of Error Detection for Candidate Rules to Detect Systematic Error* Intrainstrument SD Units * Abbreviations are explained in the footnote to Table 1. Potassium Creatine Kinase Iron Response to Random Error Figures 5, 6, and 7 are graphs of the performance characteristics of selected rules for random error for potassium, CK, and iron, respectively. The x-axes of these figures are labeled in terms of random error: 1.0 s i, corresponding to the probability of false rejection (P fr, only the inherent random error of the method is present); 2.0 s i, a doubling of random error; and 3.0 s i, a tripling of random error. As with systematic error, rules that perform well for potassium and even for CK have low sensitivity to significant errors with the marginal iron method. Therefore, for iron, only the rule can detect significant random errors with higher probability than the probability to fail PT. In comparison, QC rules for routine internal control also have low probability to detect random error. For a doubling of random error, the 1 3s /2 2s control procedure with 2 controls 8 has P ed of roughly.30 for detecting the increased error. For a tripling of random error, the same control procedure has P ed of roughly.60 for detecting the increased error. Table 5 summarizes the performance of the rules we studied for detection of random error. Suggested Combination Rule No single rule performs optimally across the range of method quality and s g /s i ; however, we were able to combine 3 rules sensitive to systematic and random errors for analytes with different method qualities to create a combination rule with broad sensitivity to systematic and random errors. The combination rule x 1.5 SDI / /R 4.0 SDI has sensitivity to systematic and random errors across the range of method quality we studied. Its P fr is high only for marginal methods. Power functions for this rule for systematic and random errors are shown in Figures 8 and 1000 Arch Pathol Lab Med Vol 129, August 2005 Self-Interpretation of Proficiency Testing Data Carey et al
5 Figure 5. Performance characteristics of selected proficiency testing (PT) rules for random error for potassium (mean s g /s i, 1.23; mean E A /s i, 7.1). P ed indicates the probability for error detection. Figure 6. Performance characteristics of selected proficiency testing (PT) rules for random error for creatine kinase (mean s g /s i, 1.70; mean E A /s i, 3.8). P ed indicates the probability for error detection. Table 5. R 3.0 SDI R 4.0 SDI Probability of Error Detection for Candidate Rules to Detect Random Error* /5 x &1 50% EA x 1.5 SDI / /R 4.0 SDI R 3.0 SDI R 4.0 SDI /5 x &1 50% EA x 1.5 SDI / /R 4.0 SDI Multiples of Intrainstrument SD Potassium Creatine Kinase Iron R 3.0 SDI R 4.0 SDI /5 x &1 50% EA x 1.5 SDI / /R 4.0 SDI * Abbreviations are explained in the footnote to Table 1. Figure 7. Performance characteristics of selected proficiency testing (PT) rules for random error for iron (mean s g /s i, 2.68; mean E A /s i, 2.9). P ed indicates the probability for error detection. 9. As method quality increases from marginal to Six Sigma, false rejections range from 16% to nearly zero, and the probability of detecting a shift equal to 2 times the intrainstrument SD ranges from 94% for the marginal method to 69% for the Six Sigma method. COMMENT Previously, screening PT data was recommended with the 2 1s rule and confirming error with the x 1.0 SDI,R 4.0 SDI,,1 1.5 SDI,andR 3.0 SDI rules, depending on the s g /s i of the method. 2,9 That work did not consider the relationship of allowable error and the s g /s i of the method and the ultimate risk of PT failure. The present work shows that this pathway had (1) high probability of false rejections and sensitivity to small, possibly insignificant errors for high-quality methods and (2) low sensitivity for significant errors for low-quality methods. We have become aware of more optimally performing rules that are based on the PT allowable error rather than the SDI. The rule we Arch Pathol Lab Med Vol 129, August 2005 Self-Interpretation of Proficiency Testing Data Carey et al 1001
6 Figure 8. Performance characteristics of x 1.5 SDI / /R 4.0 SDI combination rule for systematic error. P ed indicates the probability for error detection; CK, creatine kinase; and K, potassium. Figure 9. Performance characteristics of x 1.5 SDI / /R 4.0 SDI combination rule for random error. P ed indicates the probability for error detection; CK, creatine kinase; and K, potassium. are suggesting as the outcome of the present study, the x 1.5 SDI / /R 4.0 SDI combination rule, is much more reliable for detecting quality failures that threaten PT failure, if not corrected, and focuses remedial effort on lowerquality methods where PT failure is much more likely to occur. Proficiency testing results provide an opportunity for participants to detect errors that have been missed by their usual internal QC procedures, because internal QC limits are inappropriately large or the errors were missed during review of internal QC data, or because of matrix differences between the QC materials and the PT materials. Proficiency testing results potentially have higher probability to detect errors than internal QC results from a single run because there are 5 samples in a PT challenge versus the customary 2 or 3 samples used in internal QC. When a participant reviews the results of a PT event to check for rule failures, the SDI results and the pictorial display of the results must be examined. The pictorial display of results on College of American Pathologists survey reports makes it easy for the participant to detect and 5 x &1 50% EA rule failures. Examples of these failures are Figure 10. Example plots of the relative distance of results from targets as percentages of allowed deviation from a College of American Pathologists survey report demonstrating 1 75%EA (survey set C-C, 2003) and 5 x &1 50% EA (survey set C-B, 2003) rule failures. shown in Figure 10 as C-C and C-B, respectively. (Note added in proof: For 2005 surveys, CAP has changed the format and reduced the size of these plots.) We recommend inspecting PT data with the x 1.5 SDI / /R 4.0 SDI combination rule. It has high sensitivity to systematic and random errors that have significant probability of causing PT failure regardless of method quality. The x 1.5 SDI and R 4.0 SDI rules are sensitive to systematic and random errors, respectively, for high-quality methods and have near zero probability of false rejection. When PT data fail either of these rules, bias or random error is almost certain to be present. For mid- to low-quality methods, the rule is sensitive to systematic and random errors. When there is a failure of the rule, follow-up is necessary to determine whether the cause of the failure is systematic or random error or a false rejection. If the PT data also fail the 5 x &1 50% EA rule, systematic error is likely because sensitivity of this rule to systematic error is as good as that of the rule, after allowance for the P fr of the latter. For the analytes we studied, P fr for the 5 x &1 50% EA rule is.034 or less. The x 1.0 SDI rule, with P fr approaching zero, is also useful for confirming systematic error in intermediate-quality methods if there is failure of the rule without failure of the x 1.5 SDI rule. We do not recommend screening with the x 1.0 SDI rule because it is sensitive to small, probably insignificant systematic errors for Six Sigma methods. For all methods, comparison of internal QC data from the date of the PT event with peer group data may help confirm the presence of bias. Investigating rule failures for intermediate- and marginal-quality methods is difficult because of its high P fr (.16 for iron) and the lack of sensitivity of other rules for random error. If the PT data also fail the R 3.0 SDI rule, random error is confirmed; however, PT failure is more likely to occur than R 3.0 SDI rule failure (and even R 2.0 SDI rule failure 2 ) as random error increases for iron. The R 3.0 SDI rule is more sensitive to random error for CK (P ed for doubling of random error is.407 vs probability of PT failure of.059). Review of QC data from the time of the PT event for indications of random error may be helpful. Sometimes it is impossible to confirm whether a rule failure represents random error or false rejection. In this case, a check of within-run precision by running 5 to 10 replicates of control material or a patient specimen, calculating the within-run SD, and comparing it with the manufacturer s claim for within-run precision may be the simplest way to decide whether increased random error is present. Fig Arch Pathol Lab Med Vol 129, August 2005 Self-Interpretation of Proficiency Testing Data Carey et al
7 Figure 11. Flowchart for interpreting proficiency testing (PT) data with the recommended combination rule. QC indicates quality control. ure 11 is a flowchart for interpreting PT data with the recommended combination rule. Ultimately, a laboratory s PT performance for a particular method is limited by the inherent quality of the method. For example, if the best precision a laboratory can achieve with a given method is at the 3.0 Sigma level, this method is a potential source of PT problems. Laboratories must consider method quality during the selection process and, whenever possible, select methods with the best analytic performance. Information is available in manufacturers package inserts and published method evaluations. Then, the method must be evaluated to demonstrate that the user can achieve the quality the manufacturer has claimed. Clinical Laboratory Standards Institute (formerly NCCLS) guideline EP15-A provides a procedure for accomplishing this with minimal experimental effort. 10 Garber and Carey 4 and Westgard 11 provide guidance for performing method evaluations and interpreting method evaluation data. To maintain precision, laboratories should review method quality as new lots of control materials are introduced, by comparing the SD used to set control limits (representing the true performance of the QC procedure) with allowable error by calculating the Process Sigma (E A / s i ). Whenever the Process Sigma is less than 4, QC ranges must be carefully set to maintain sensitivity to error, and control failures must be investigated and problems corrected. If there is a high prevalence of errors, more sensitive control procedures should be implemented. These methods should be scrutinized in daily operation and should be improved or replaced. Whenever a laboratory selects a multitest automated testing system, there is a compromise of the quality of 1 or more methods to gain the other benefits of automation. Some analytes are generally problematic because state-ofthe-art precision performance is marginal with respect to allowable error; sodium and chloride are examples. There are problems when PT samples have low concentrations of some analytes, for example, urea nitrogen and whole blood ethanol. These 4 analytes have been sources of near misses in our laboratories. We thank Ray Gambino, MD, and Peter Mallon, PhD, for creating the concept of a near miss in reviewing PT in the late 1980s at Quest Diagnostics, Incorporated (MetPath, Inc, Teterboro, NJ). A near miss was defined as a result that was in the outer 25% of the acceptable range. This situation prompted an investigation into the cause for that result being so far off target and required implementation of appropriate corrective action, to prevent further degradation and failure on the next event. References 1. Medicare, Medicaid and CLIA programs: regulations implementing the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 57 Federal Register 7002 (1992). 2. Cembrowski GS, Hackney JR, Carey RN. The detection of problem analytes in a single proficiency test challenge in the absence of Health Care Financing Administration rule violations. Arch Pathol Lab Med. 1993;117: College of American Pathologists. Comprehensive Chemistry Survey: Set C- C. Northfield, Ill: College of American Pathologists; Garber CC, Carey RN. Evaluation of methods, In: Kaplan LA, Pesce AJ, eds. Clinical Chemistry: Theory, Analysis and Correlation. 4th ed. St Louis, Mo: CV Mosby Co; 2003: College of American Pathologists. Quality Assurance Services: Group Summary Report: Lot-Date Data Through June 1991, for Controls XLS-71 and XPS Northfield, Ill: College of American Pathologists; Westgard JO. Six Sigma Quality Design and Control. Madison, Wis: Westgard QC Inc; Ontario Medical Association. Cardiac Markers 0104: Survey Report. Toronto, Ontario: Laboratory Proficiency Testing Program, Ontario Medical Association; April Westgard JO, Barry PL, Hunt MR, Groth T. A multi-rule Shewhart chart for quality control in clinical chemistry. Clin Chem. 1981;27: Cembrowski GS. Thoughts on quality-control systems: a laboratorian s perspective. Clin Chem. 1997;43: Clinical Laboratory Standards Institute (formerly NCCLS). User Demonstration of Performance for Precision and Accuracy: Approved Guideline. Wayne, Pa: NCCLS; CLSI document EP15-A. 11. Westgard JO. Basic Method Validation. Madison, Wis: Westgard QC Inc; Arch Pathol Lab Med Vol 129, August 2005 Self-Interpretation of Proficiency Testing Data Carey et al 1003
Total Analytic Error From Concept to Application
Página 1 de 5 Clinical Laboratory News Subscribe CLN Daily CLN Stat CLN Articles Total Analytic Error From Concept to Application Author: James O. Westgard, PhD, and Sten A. Westgard, MS // Date: SEP.1.2013
More informationDesigning QC Activities to More Precisely Manage Analytical Accuracy and Patient Risk
Designing QC Activities to More Precisely Manage Analytical Accuracy and Patient Risk Curtis A. Parvin, Ph.D. Manager of Advanced Statistical Research Bio-Rad Laboratories, QSD curtis_parvin@bio-rad.com
More informationPractical Guide to Running Controls
Practical Guide to Running Controls Internal quality control Introduction In addition to the competenceof the lab managerand the technical validation, the use and proper management of quality control (IQC,
More informationARTICLES IMPACT STATEMENT ... September : JALM 211. Hassan Bayat, 1 Sten A. Westgard, 2 and James O.
Planning Risk-Based Statistical Quality Control Strategies: Graphical Tools to Support the New Clinical and Laboratory Standards Institute C24-Ed4 Guidance Hassan Bayat, 1 Sten A. Westgard, 2 and James
More informationEstablishing Quality Control Target Values and Standard Deviations for Hematology Instrumentation
Establishing Quality Control Target Values and Standard Deviations for Hematology Instrumentation For informational purposes only. WHO REQUIRES IT AND WHAT THEY REQUIRE Regulatory agencies require the
More informationQuality Control in clinical laboratory. Kanit Reesukumal, M.D. Assistant Professor Clinical Pathology Mahidol University
Quality Control in clinical laboratory Kanit Reesukumal, M.D. Assistant Professor Clinical Pathology Mahidol University Outline Internal Quality Control Calculation Levey-Jennings Charts Westgard Rules
More informationMeasurement Uncertainty Guide. ISO Accreditation Program
Measurement Uncertainty Guide ISO 15189 Accreditation Program Background Why This is Necessary The ISO 15189:2012 standard contains enhanced expectations regarding measurement uncertainty (MU) in clause
More informationFederal regulations (Clinical Laboratory Improvement
alibration Verification Performance Relates to Proficiency Testing Performance Martin H. roll, MD; Patricia E. Styer, PhD; Delmiro Anthony Vasquez, MT(ASP) ontext. Since 1988, the ollege of American Pathologists
More informationAllowable Imprecision for Laboratory Tests Based on Clinical and Analytical Test Outcome Criteria
CUN. CHEM. 40/10, 1909-1914 (1994) #{149} Laboratory Management and Utilization Allowable Imprecision for Laboratory Tests Based on Clinical and Analytical Test Outcome Criteria James 0. Westgard, Julie
More informationNational External Quality Assurance Program Pakistan (NEQAPP) a milestone in proficiency testing in Pakistan
National External Quality Assurance Program Pakistan (NEQAPP) a milestone in proficiency testing in Pakistan Muhammad Usman Munir 1, Aamir Ijaz 2 1 Department of Pathology, Combined Military Hospital,
More informationCommon Deficiencies
Question text Deficiency #12: Does the laboratory have a documented system to ensure consistency of morphologic observations among all personnel performing (U/A, Micro, Hem) (sample) Suggested methods
More informationACCESS Immunoassay System. HIV combo QC4 & QC5. For monitoring the system performance of the Access HIV combo assay. B71107A - [EN] /01
ACCESS Immunoassay System HIV combo QC4 & QC5 B22822 For monitoring the system performance of the Access HIV combo assay. - [EN] - 2015/01 Table of Contents Access HIV combo QC4 & QC5 1 Intended Use...
More informationQuality Management of the Total Examination Process. Elvar Theodorsson
Quality Management of the Total Examination Process Elvar Theodorsson 2 The total testing chain consists of much more than the analytical phase The true value of laboratory results are expressed in their
More informationVariability of Laboratory Test Results
Clinical Chemistry / VARIABILITY OF LABORATORY TEST RESULTS Variability of Laboratory Test Results Shahram Shahangian, PhD, 1 and Richard D. Cohn, PhD 2 Key Words: Variability of laboratory results; Laboratory
More informationProficiency Testing Schemes and Traceability: the College of American Pathologists (CAP) Perspective John H. Eckfeldt, MD, PhD
Proficiency Testing Schemes and Traceability: the College of American Pathologists (CAP) Perspective John H. Eckfeldt, MD, PhD Medical Director, Clinical Pathology, Fairview-University Medical Center Professor,
More informationQUALITY CONTROL & STANDARD OPERATING PROCEDURES EHI JAMES OCHEIKWU.
QUALITY CONTROL & STANDARD OPERATING PROCEDURES EHI JAMES OCHEIKWU. OUTLINE Introduction Quality Control - Meaning Types of Quality Control Monitoring of Quality Control Multi-rule Quality Control Quality
More informationPlan Subject Index Number Section Subsection Category Contact Last Revised References Applicable To Detail PRINCIPLE:
Subject Quality Assurance for Laboratory Testing Index Number Lab-0135 Section Laboratory Subsection Laboratory - General Category Departmental Contact Nancy Ekern Last Revised 7/27/2017 References Required
More informationS1725 Method Validation and Verification: Case Studies and Laboratory Challenges
S1725 Method Validation and Verification: Case Studies and Laboratory Challenges James H. Nichols, PhD, D(ABCC) Lauren N. Person, DO, MPH, FCAP Objectives Identify the difference between method validation
More informationInternal Quality Control Practices in Coagulation Laboratories: recommendations based on a patterns-of-practice survey
International Journal of Laboratory Hematology ORIGINAL ARTICLE The Official journal of the International Society for Laboratory Hematology INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY Internal Quality
More informationVerifying New Reagent Lot Performance
Verifying New Reagent Lot Performance Julianne Addison Application Consultant, Siemens RSC Answers for life. Objectives Describe issues relating to changing reagent lots Discuss the reasons QC material
More informationVerification of Method XXXXXX
Reviewed By: Date: Technical Supervisor Reviewed By: Date: General Supervisor Reviewed By: Date: Quality Assurance Coordinator Approved By: Date: Director Page 1 of 11 Table of Contents Purpose and Principle:...
More informationQuality Control for Chemistry Laboratory Dynacare Kasper Laboratories Procedures
54 Quality Control for Chemistry Laboratory Dynacare Kasper Laboratories Procedures Lorena Ivona Stefan 1*, Deborah Reid 2 1. Emergency Clinical Hospital, Laboratory Medical Analysis, Craiova, Romania
More informationGuide to Fulfillment of Validation and Verification of Examination Requirements
DIAGNOSTIC ACCREDITATION PROGRAM College of Physicians and Surgeons of British Columbia 300 669 Howe Street Telephone: 604-733-7758 ext. 2635 Vancouver BC V6C 0B4 Toll Free: 1-800-461-3008 (in BC) www.cpsbc.ca
More informationImplementation Guide. 3a. Skills Checklist. 3b. Competency Exam. 3c. Answer Key: Competency Exam. 3d. Competency Assessment Checklist
Implementation Guide TABLE OF CONTENTS SECTION 1 Introduction SECTION 2 Pre-Implementation Checklist SECTION 3 Introduction: Operator Training and Competency Certification 3a. Skills Checklist 3b. Competency
More informationAdvances in Biochemistry & Applications in Medicine
Advances in Biochemistry & Applications in Medicine Chapter 1 ISBN: 978-93-87500-49-5 Quality Control in a Clinical Laboratory Vaneet Kaur 1 ; Pawan Kumar Kare 1* ; Himanshu Madaan 1 1 Department of Biochemistry,
More informationGuide to Fulfillment of Laboratory Results Comparability Requirements
DIAGNOSTIC ACCREDITATION PROGRAM College of Physicians and Surgeons of British Columbia 300 669 Howe Street Telephone: 604-733-7758 ext. 2635 Vancouver BC V6C 0B4 Toll Free: 1-800-461-3008 (in BC) www.cpsbc.ca
More informationValidation of a quality assessment system for blood gas and electrolyte testing
Clinica Chimica Acta 382 (2007) 65 70 www.elsevier.com/locate/clinchim Validation of a quality assessment system for blood gas and electrolyte testing John G. Toffaletti a,, Elizabeth H. McDonnell a, Lakshmi
More informationMOLECULAR TESTING: VERIFYING/VALIDATING INSTRUMENTS, REAGENTS AND ASSAYS. Richard L. Hodinka, Ph.D.
MOLECULAR TESTING: VERIFYING/VALIDATING INSTRUMENTS, REAGENTS AND ASSAYS Richard L. Hodinka, Ph.D. University of South Carolina School of Medicine Greenville Greenville Health System, Greenville, SC hodinka@greenvillemed.sc.edu
More informationValidating, Verifying, and Evaluating Your Test Methods: It s NOT a Regulatory Exercise!
Validating, Verifying, and Evaluating Your Test Methods: It s NOT a Regulatory Exercise! Pat Garrett, Ph.D., DABCC Renee Howell, Ph.D., MT(ASCP) SeraCare Life Sciences, Inc. AACC Annual Meeting July 29,
More informationUrinalysis and Body Fluids CRg. Laboratory Regulation. Laboratory Regulation for Quality Assessment. Unit 1 B. Quality Assessment
Urinalysis and Body Fluids CRg Unit 1 B Laboratory Regulation Federal Regulations / Regulatory Organizations Laboratory structure / operation Quality test performed by qualified personnel to obtain quality
More informationA Practical Guide to Internal Quality Control (IQC) For Quantitative Tests in Medical Laboratories, Version 2.0 February 2015
Dear Colleagues, A Practical Guide to Internal Quality Control (IQC) For Quantitative Tests in Medical Laboratories, Version 2.0 February 2015 Time flies! This is a substantial revision of the previous
More informationInterpretation of External Quality Assurance: How to and How Not to
Original Article Interpretation of External Quality 10.5005/jp-journals-10054-0044 Assurance: How to and How Not to Interpretation of External Quality Assurance: How to and How Not to 1 Satish Ramanathan,
More informationMaster. Chemistry and Toxicology Checklist. CAP Accreditation Program
Master Chemistry and Toxicology Checklist CAP Accreditation Program College of American Pathologists 325 Waukegan Road Northfield, IL 60093-2750 www.cap.org 08.17.2016 2 of 76 Disclaimer and Copyright
More informationWhat is? An Overview of Operational Processes
Friday April 7, 2017 LD4 What is? An Overview of Operational Processes John T. Daly, MD, FCAP Chief Medical Officer, COLA DESCRIPTION: This session focuses on other important topics for the laboratory
More informationStrengthening Laboratory Management Toward Accreditation. Module 6: Quality Assurance
Strengthening Laboratory Management Toward Accreditation Module 6: Quality Assurance Key Message My lab assures accurate and reliable testing processes. Desired Outcome Consistently accurate and reliable
More informationThe International Haemostasis External Quality Control Program
The International Haemostasis External Quality Control Program Intended use of Quality Control Primary Purpose of the Clinical Laboratory To produce accurate results that will correctly diagnose and interpret
More informationToday s Featured Speaker
Today s Featured Speaker Judy Yost, M.A., M.T.(ASCP) received her B.S. Degree at Wilkes College and her M.A. in hospital management from Central Michigan University. She is an American Society for Clinical
More informationSAMPLE. Evaluation of Total Analytical Error for Quantitative Medical Laboratory Measurement Procedures
2nd Edition EP21 Evaluation of Total Analytical Error for Quantitative Medical Laboratory Measurement Procedures This guideline provides manufacturers and end users with an understanding of concepts related
More informationToday s Featured Speaker
Today s Featured Speaker Judy Yost, M.A., M.T.(ASCP) received her B.S. Degree at Wilkes College and her M.A. in hospital management from Central Michigan University. She is an American Society for Clinical
More information2008 HFC-A PARTICIPANT SUMMARY
2008 HFC-A PARTICIPANT SUMMARY Evaluation Criteria Analyte Target Value Evaluation Criteria Red Blood Cell Peer Group ± 3 SD White Blood Cell Peer Group ± 3 SD Cytopreparation Differential Educational
More informationASVCP quality assurance guidelines: control of general analytical factors in veterinary laboratories
Veterinary Clinical Pathology ISSN 0275-6382 SPECIAL REPORT ASVCP quality assurance guidelines: control of general analytical factors in veterinary laboratories Bente Flatland 1, Kathy P. Freeman 2, Kristen
More informationUSE OF INFORMATICS IN ANALYTICAL QUALITY
USE OF INFORMATICS IN ANALYTICAL QUALITY DR SUVIN SHETTY MD HEAD, DEPT OF LABORATORY MEDICINE DR L H HIRANANDANI HOSPITAL, MUMBAI 4/14/2017 Dr Suvin Shetty, Informatics In Analytical Quality 1 DR L H HIRANANDANI
More informationVerification or validation, that is the question
Perspective Page 1 of 7 Verification or validation, that is the question Giorgia Antonelli 1, Andrea Padoan 1, Ada Aita 1, Laura Sciacovelli 2, Mario Plebani 1,2 1 U.O.C. of Laboratory Medicine, Department
More informationCLSI C60: Assay Validation & Post-Validation Monitoring
CLSI C60: Assay Validation & Post-Validation Monitoring Ross J. Molinaro, MT(ASCP), PhD, DABCC, FACB Medical Director Core Laboratory, Emory University Hospital Midtown Emory Clinical Translational Research
More informationLaboratory Accreditation Test Validation: A Brave New World for Anatomic Pathology
Laboratory Accreditation Test Validation: A Brave New World for Anatomic Pathology Francis E. Sharkey, MD, FCAP University of Texas Health Science Center, San Antonio, TX Richard W. Brown, MD, FCAP Memorial
More informationGuidance for Industry and FDA Staff. Replacement Reagent and Instrument Family Policy
Guidance for Industry and FDA Staff Replacement Reagent and Instrument Family Policy Document issued on: December 11, 2003 This document supersedes Data for Commercialization of Original Equipment Manufacturers
More informationEstablishing Chemistry QC Ranges
Chemistry Guideline for Establishing New Control Lot Means and Quality Control (QC) Ranges Through Parallel Testing and Historic Coefficient of Variation (%CV h ) Authored by Kurt Michael and Paul Richardson
More informationThe road to a perfect EQA-programme
The road to a perfect EQA-programme The Dutch SKML experience Christa Cobbaert DEPARTMENT OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE, LEIDEN UNIVERSITY MEDICAL CENTRE, LEIDEN, THE NETHERLANDS Content
More informationWhich skills are needed and how they should be gained by laboratory medicine professionals for successful ISO accreditation
Meeting the needs of Mediterranean nations: improving efficiency in laboratory medicine This is a Platinum Open Access Journal distributed under the terms of the Creative Commons Attribution Non-Commercial
More informationLabGuide 13 How to Verify Performance Specifications
1 LG 13 Comments? Feedback? Questions? Email us at info@cola.org or call us at 800 981-9883 LabGuide 13 How to Verify Performance Specifications The verification of performance specifications confirms
More informationCLIA Personnel & Competency Requirements
Friday April 7, 2017 D32 CLIA Personnel & Competency Requirements John T. Daly, MD, FCAP Chief Medical Officer, COLA DESCRIPTION: In addition to the laboratory director, the CLIA regulations specify personnel
More informationReady, Set, Test! AACC Conference Mass Spectrometry in the Clinical Lab: Best Practice and Current Applications September 17-18, 2013 St.
Ready, Set, Test! Ross Molinaro, PhD, MLS(ASCP) CM, DABCC, FACB Medical Director, Clinical Laboratories Emory University Hospital Midtown Emory Clinical Translational Research Laboratory AACC Conference
More informationWAIT! Ready, Set, Test! Financial Disclosure. Research/Educational grants/consulting/salary support
Ready, Set, Test! Ross Molinaro, PhD, MLS(ASCP) CM, DABCC, FACB Medical Director, Clinical Laboratories Emory University Hospital Midtown Emory Clinical Translational Research Laboratory AACC Conference
More informationAssay Validation Services
Overview PierianDx s assay validation services bring clinical genomic tests to market more rapidly through experimental design, sample requirements, analytical pipeline optimization, and criteria tuning.
More informationSMILE Johns Hopkins University Baltimore, MD USA. Guidelines for Manual Evaluation of CAP Hemocytometer Fluid Count
SMILE Johns Hopkins University Baltimore, MD USA Guidelines for Manual Evaluation of CAP Hemocytometer Fluid Count Author: Heidi Hanes, BS, MT (ASCP) SH Document Number: Pro22-25 Effective (or Post) Date:
More informationSAMPLE. Establishing and Verifying an Extended Measuring Interval Through Specimen Dilution and Spiking
1st Edition EP34 Establishing and Verifying an Extended Measuring Interval Through Specimen Dilution and Spiking It is often medically necessary to provide results for specimens with concentrations above
More informationQuality Control Program
Quality Control Program Online Interlaboratory Comparison Program C Quality Control Program C Quality Control Program Get the most Powerful Program to Pilot your Analytical Performance Intelligent and
More informationISO 13528:2015 Statistical methods for use in proficiency testing by interlaboratory comparison
ISO 13528:2015 Statistical methods for use in proficiency testing by interlaboratory comparison ema training workshop August 8-9, 2016 Mexico City Class Schedule Monday, 8 August Types of PT of interest
More informationLabDAQ Laboratory Information System (LIS) is a scalable solution trusted by thousands of physicians and laboratory professionals every day.
Sample Reports LabDAQ Laboratory Information System (LIS) is a scalable solution trusted by thousands of physicians and laboratory professionals every day. Experience the power of LabDAQ. Table of Contents
More informationCOMMISSION ON LABORATORY ACCREDITATION. Laboratory Accreditation Program CHEMISTRY AND TOXICOLOGY CHECKLIST
Revised: 04/06/2006 COMMISSION ON LABORATORY ACCREDITATION Laboratory Accreditation Program CHEMISTRY AND TOXICOLOGY CHECKLIST Disclaimer and Copyright Notice The College of American Pathologists (CAP)
More informationDiscover the Importance of Third Party Quality Control
Bio-Rad Laboratories Q U A L I T Y C O N T R O L Discover the Importance of Third Party Quality Control Introduce Your Laboratory to an Independent Assessment Bio-Rad Laboratories Q U A L I T Y C O N T
More informationIQCP for Commercial Antimicrobial Susceptibility Testing (AST) System XYZ
Please note that some references to protocol, publications, performance data etc. are fictitious in this EXAMPLE. Please use your own DATA for your IQCP. The following represents one example of how you
More informationCase Study College of American Pathologists. All rights reserved. cap.org
Case Study How to Reduce Clerical Errors Mark Shearer, MCLT, MT(ASCP) Director of Chemistry, CompuNet Clinical Laboratories Clerical errors represent the single largest source of errors on proficiency
More informationImportance of Third Party Quality Controls
QUALITY CONTROL Importance of Third Party Quality Controls Complete QC solutions for results you can trust Quality Control qual-ity con-trol Noun A system of maintaining standards in manufactured products
More informationStatements on the Regulation of Laboratory Developed Tests
Statements on the Regulation of Laboratory Developed Tests Current Regulatory Gaps and Perspectives on Oversight of LDTs American Cancer Society Cancer Action Network says Molecular tests, in particular,
More informationExternal Quality Assurance Scheme (EQAS): Criteria for Evaluating Performance of a Laboratory
IOSR Journal of Biotechnology and Biochemistry (IOSR-JBB) ISSN: 2455-264X, Volume 4, Issue 4 (Jul. Aug. 2018), PP 16-20 www.iosrjournals.org External Quality Assurance Scheme (EQAS): Criteria for Evaluating
More informationLaboratory Developed Tests. William Castellani, MD Inter-regional Commissioner Clinical Pathologist, Penn State Hershey Medical Center
Laboratory Developed Tests William Castellani, MD Inter-regional Commissioner Clinical Pathologist, Penn State Hershey Medical Center Objectives Compare and contrast new test validation requirements for
More informationImprovement of the Quality of Work in a Biochemistry Laboratory via Measurement System Analysis
Chinese Journal of Physiology 59(5): 93-99, 016 93 DOI: 10.4077/CJP.016.BAF45 Improvement of the Quality of Work in a Biochemistry Laboratory via Measurement System Analysis Ming-Shu Chen 1, Chen-Mao Liao,
More informationDefining Analytical Performance Specifications
Defining Analytical Performance Specifications Matthias Orth IFCC Committee on Clinical Laboratory Management - http://www.ifcc.org/ifcc-education-division/emd-committees/c-clm/ Satellite Educational Workshop
More informationWEQAS: what is it and what does it mean?. Celia Critchley Point of Care Co-ordinator Warrington and Halton Hospitals NHS Foundation Trust
WEQAS: what is it and what does it mean?. Celia Critchley Point of Care Co-ordinator Warrington and Halton Hospitals NHS Foundation Trust Objectives Overview of External Quality Assessment and its relevance
More informationCompetency Assessment: Is Your Program Competent? Judy Sullivan, MS, MT(ASCP)SBB HAABB Meeting April 30, 2013
Competency Assessment: Is Your Program Competent? Judy Sullivan, MS, MT(ASCP)SBB HAABB Meeting April 30, 2013 Objectives Discuss requirements related to competency assessment Describe what assessors, inspectors,
More informationGuidelines for Use of Back-Up Equipment and Back-up Clinical Laboratories for Safety Testing in DAIDS-Sponsored Clinical Trials
Notes An earlier version of this document was drafted by Paul Richardson, Estelle Piwowar-Manning, Erin Gover, and Kurt Michael. The document was finalized by the Cross-Network Laboratory Focus Group (LFG),
More informationClinical Chemistry Approach to Evaluation of Commutability
Clinical Chemistry Approach to Evaluation of Commutability Hubert W. Vesper, Ph.D. Director, Clinical Standardization Programs Division of Laboratory Sciences Centers for Disease Control and Prevention,
More informationFor In Vitro Diagnostic Use
SYNCHRON System(s) Chemistry Information Sheet Lactate Dehydrogenase REF 442660 For In Vitro Diagnostic Use ANNUAL REVIEW Reviewed by: Date Reviewed by: Date PRINCIPLE INTENDED USE reagent, when used in
More informationDate. Albumin measurements are used in the diagnosis and treatment of numerous diseases primarily involving the liver and/or kidneys.
SYNCHRON System(s) Chemistry Information Sheet Copyright 2013 Beckman Coulter, Inc. Albumin REF 442765 For In Vitro Diagnostic Use ANNUAL REVIEW Reviewed by Date Reviewed by Date PRINCIPLE INTENDED USE
More information2009 LAP Audioconference Series. Simple Tests, Tough Problems Patient Care and Laboratory Inspection in Coagulation
2009 LAP Audioconference Series Simple Tests, Tough Problems Patient Care and Laboratory Objectives: After participating in this session, you will be able to: to describe patient care and accreditation
More informationMarch 19, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852
March 19, 2018 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852 RE: Docket No. FDA-2017-D-6765; Draft Guidance for Industry and Food
More informationLaboratory Quality Control Management System. A New Approach to Quality Control
Laboratory Quality Control Management System A New Approach to Quality Control Overview Provide hospitals and reference laboratories with tools to capture Quality Control (QC)/Proficiency Testing (PT)
More informationSeptember 8, General Comments:
September 8, 2009 AMP Comments on the draft report from the Agency for Healthcare Research and Quality (AHRQ): AHRQ Draft Report on Quality, Regulation and Clinical Utility of Laboratorydeveloped Tests.
More informationConfirm assay performance Identify poor assay performance. Confirm correction of poor performance
Performance criteria for EQA schemes need for harmonization Graham Jones Department of Chemical Pathology St Vincent s Hospital, Sydney Milan November 2014 The Role of External Quality Assurance Confirm
More information- - - Backup_Lab_Guidelines v
- - - Backup_Lab_Guidelines v2.0 2010-11-10 Table of Contents Introduction... 1 Back-Up Guidelines for Safety Testing Laboratories... 2 Introduction... 2 Development and review of the back-up plan... 2
More informationSEED HAEMATOLOGY. SNCS IQAS Online the quality control solution for the haematology laboratory
SYSMEX EDUCATIONAL ENHANCEMENT AND DEVELOPMENT NOVEMBER 2015 SEED HAEMATOLOGY SNCS IQAS Online the quality control solution for the haematology laboratory Introduction It is standard practice for laboratories
More informationThe Validity of Proficiency Testing: A Review of Data from the College of American Pathologists Laboratory Improvement Programs
1995 Institute: Frontiers in Laboratory Practice Research 95 The Validity of Proficiency Testing: A Review of Data from the College of American Pathologists Laboratory Improvement Programs Noel S. Lawson,
More informationQuality Control: Tips, Troubleshooting, and Tidbits
Quality Control: Tips, Troubleshooting, and Tidbits Nancy May, MBA, MT(ASCP) Technical Integration Specialist Agenda: 4 Tips 2 Troubleshootings Tools: Detector Parameters XbarM Tidbits 2 Sysmex America
More informationCONCURRENT 10: THE COMPLETE BLOOD COUNT AND BEYOND: QUALITY ISSUES AND REFERENCE METHODS
CONCURRENT 10: THE COMPLETE BLOOD COUNT AND BEYOND: QUALITY ISSUES AND REFERENCE METHODS Saturday May 14 th 2016 1:30 3:00 PM (13.30 15.00hrs) International Society for Laboratory Hematology (ISLH) CONCURRENT
More informationA Verification Study for Implementing the Revised CLSI Breakpoints. Summary. Breakpoint Differences Cephalosporin Breakpoints for Enterobacteriaceae
A Verification Study for Implementing the Revised CLSI Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance National Center for Emerging and Zoonotic Infectious Disease
More informationA Verification Study for Implementing the Revised CLSI Breakpoints. Summary. Glossary CDC 1
A Verification Study for Implementing the Revised CLSI Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance National Center for Emerging and Zoonotic Infectious Disease
More informationReference systems and international standardisation of measurements for clinically important enzymes
Reference systems and international standardisation of measurements for clinically important enzymes VII th Czech National Congress of Clinical Biochemistry (11. 13.9.2005, Olomouc) Gerhard Schumann, Klinische
More informationQuality Assurance by Liz McChlery
Quality Assurance by Liz McChlery Define QA and Total Quality Management Describe Quality Control Define and distinguish Accuracy and Precision Define a Biological Reference Interval Describe ISO15189
More informationMaster. Immunology Checklist. CAP Accreditation Program
Master Immunology Checklist CAP Accreditation Program College of American Pathologists 325 Waukegan Road Northfield, IL 60093-2750 www.cap.org 08.17.2016 2 of 33 Disclaimer and Copyright Notice On-site
More informationMonitoring and improvement of intralaboratory turnaround time at the university hospital Campus Bio-Medico in Rome
SCIENTIFIC PAPERS CONTRIBUTI SCIENTIFICI Monitoring and improvement of intralaboratory turnaround time at the university hospital Campus Bio-Medico in Rome Silvia Angeletti 1, Marina De Cesaris 1, Siriana
More informationIQCP for the Akers Bio PIFA PlussPF4 Rapid Assay
On December 31, 2015 the ability to use Equivalent Quality Control (EQC) policies will expire. Laboratories will be required to either follow the quality control regulations as outlined in CLIA 88 or develop
More informationSysmex Educational Enhancement and Development No
SEED Haematology Sysmex Educational Enhancement and Development No 2 2015 SNCS the quality control solution for the haematology laboratory The purpose of this newsletter is to provide an overview of the
More informationSAMPLE. Risk Management Techniques to Identify and Control Laboratory Error Sources; Approved Guideline Second Edition
November 2009 Risk Management Techniques to Identify and Control Laboratory Error Sources; Approved Guideline Second Edition This guideline describes risk management techniques that will aid in identifying,
More informationDeveloping an Individualized Quality Control Plan (IQCP) For Cepheid s GeneXpert Diagnostic Systems
Developing an Individualized Quality Control Plan (IQCP) For BACKGROUND On January 1, 2014, the Center for Medicare and Medicaid Services (CMS) adopted an alternative Quality Control (QC) procedure that
More informationDesign and implementation of a microchemistry analyzer
Pure & App/. Chem., Vol. 68, No. 10, pp. 1837-1841, 1996. Printed in Great Britain. Q 1996 IUPAC Design and implementation of a microchemistry analyzer Nina Peled, PhD i-stat Corporation 303 College Road
More informationDiagnostic Accreditation Program 2015 Laboratory Medicine Accreditation Standards FAQ
Diagnostic Accreditation Program 2015 Laboratory Medicine Accreditation Standards FAQ If you have questions about items in the standards please email them to: laboratorymedicine@cpsbc.ca Click on an item
More informationMathematical Analysis of Cervical Cancer Screening Policies (Does the Federal Requirement Make Any Sense?)
Mathematical Analysis of Cervical Cancer Screening Policies (Does the Federal Requirement Make Any Sense?) James C. Benneyan, Ph.D. Northeastern University, Boston MA benneyan@coe.neu.edu ABSTRACT This
More informationPAB PRINCIPLE. Kit Reorder # ANNUAL REVIEW Reviewed by: Date. Date INTENDED USE
SYNCHRON CX System(s) Chemistry Information Sheet Copyright 2008 Beckman Coulter, Inc. Prealbumin Kit Reorder # 475106 For In Vitro Diagnostic Use ANNUAL REVIEW Reviewed by: Date Reviewed by: Date PRINCIPLE
More information